What You Should Know:

你应该知道的：

–

–

Evvy

艾薇

, a women’s health startup focusing on novel female biomarkers, is embarking on a pioneering study in partnership with leading fertility clinics across the United States.

，一家专注于女性新型生物标志物的女性健康初创公司，正与美国各地的领先生育诊所合作，开展一项开创性的研究。

– The landmark research initiative marks the first time a validated, commercially available vaginal microbiome test will be used specifically to predict outcomes for patients undergoing in vitro fertilization (IVF). The study aims to identify key vaginal biomarkers linked to reproductive success, potentially transforming IVF protocols.  .

– 这一具有里程碑意义的研究计划标志着首次使用经过验证的、商业可用的阴道微生物组检测方法，专门用于预测接受体外受精（IVF）患者的治疗结果。该研究旨在识别与生殖成功相关的关键阴道生物标志物，可能彻底改变IVF方案。

Addressing Critical Gaps in IVF Success Rates

解决试管婴儿成功率的关键差距

Infertility impacts approximately one in eight couples in the U.S., making IVF an increasingly utilized path to parenthood. However, the procedure currently has an average live birth rate of only 30-40% per cycle. This highlights significant gaps in understanding and mitigating factors that can lead to IVF failure before patients undergo the costly and emotionally taxing process.

美国大约每八对夫妻中就有一对面临不孕不育问题，这使得体外受精（IVF）成为一条越来越普遍的为人父母途径。然而，该手术目前每次周期的平均活产率仅为30%-40%。这凸显了在患者经历昂贵且情感上负担沉重的流程之前，理解并减轻可能导致IVF失败的因素上存在显著差距。

Compounding this, existing scientific research has already indicated connections between imbalances in the vaginal microbiome and reproductive challenges, including IVF failure, recurrent pregnancy loss, and preterm birth.  .

此外，现有的科学研究已经表明阴道微生物组失衡与生殖挑战之间存在联系，包括体外受精失败、反复流产和早产。

Leveraging Advanced Microbiome Testing

利用先进的微生物组检测技术

Evvy aims to bridge the gap between this existing research and clinical patient care. The study utilizes Evvy’s unique vaginal microbiome test, which is CLIA, CAP, and CLEP certified and validated in the peer-reviewed journal

Evvy旨在弥合现有研究与临床患者护理之间的差距。该研究利用了Evvy独特的阴道微生物组检测，这项检测获得了CLIA、CAP和CLEP认证，并在同行评审期刊中得到了验证。

Diagnostics

诊断

. This powerful test can identify over 700 microbes from a single, convenient at-home swab. Evvy has already built the world’s largest dataset related to the vaginal microbiome, including a proprietary database with hundreds of novel genomes. By applying this robust testing platform and dataset to a large patient population within partnered fertility clinics, Evvy seeks to generate actionable evidence.  .

这种强大的测试可以从单次便捷的居家拭子中识别出700多种微生物。Evvy已经建立了全球最大的与阴道微生物组相关的数据集，包含一个拥有数百个新基因组的专有数据库。通过将这一强大的测试平台和数据集应用于合作生育诊所中的大规模患者群体，Evvy旨在生成可操作的证据。

Potential for Proactive Intervention and Improved Outcomes

主动干预和改善结果的潜力

The study was meticulously designed by prominent fertility specialists alongside Evvy’s Chief Science Officer, Pita Navarro, and Chief Medical Officer, Dr. Kate McLean. The potential impact could be significant, offering new insights into why some IVF cycles fail despite patients doing everything “right”.  .

这项研究由著名的生育专家与Evvy的首席科学官皮塔·纳瓦罗和首席医疗官凯特·麦克林医生共同精心设计。其潜在影响可能是重大的，为为什么有些体外受精周期尽管患者做了一切“正确”的事情却仍然失败提供了新的见解。

“It is devastating when patients do everything ‘right’ yet still don’t get the results they hoped for,” stated Dr. Kate McLean, Chief Medical Officer at Evvy. “This study could fundamentally enhance our understanding of why some cycles fail and unlock a new, proactive tool for patients and providers to improve outcomes”..

“当患者做了一切‘正确’的事情，却仍然没有得到他们期望的结果时，这是毁灭性的，”Evvy首席医疗官凯特·麦克林博士表示。“这项研究可以从根本上加深我们对某些周期失败原因的理解，并为患者和医疗服务提供者解锁一种新的、积极的工具以改善结果。”

Building on Existing Work and Future Research

在现有工作和未来研究的基础上

This major study follows Evvy’s recent introduction of fertility-focused insights within its platform. These insights already allow users to test and understand their microbiome health before conception attempts, IVF procedures, or when investigating unexplained infertility. Evvy’s strategy involves creating solutions based on established science while actively researching areas previously neglected.

这项重要研究紧跟Evvy最近在其平台内推出的专注于生育能力的洞察。这些洞察已经使用户能够在尝试受孕、进行体外受精（IVF）流程或在调查不明原因的不孕症之前，测试并了解他们的微生物组健康状况。Evvy的战略是基于已确立的科学创建解决方案，同时积极研究以前被忽视的领域。

This IVF study is noted as the first among many planned by Evvy to validate the predictive power of vaginal microbiome testing across a spectrum of women’s health issues throughout their lives..

这项体外受精研究被Evvy视为首个计划中的研究，旨在验证阴道微生物组测试在女性一生中各种健康问题上的预测能力。